The ability to do future research and the accessability if drugs should be balanced against the percentage reinvested into research and the amount paid to hierarchy in pharmaceutical comoanies
The historical activity of users engaging with this answer.
Loading data...
Loading chart...
Loading the political themes of users that engaged with this discussion
Loading data...